We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TBRG:NASDAQTruBridge, Inc. Analysis

Data as of 2026-05-04 - not real-time

$25.74

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

TruBridge (TBRG) is trading at $25.74, comfortably above its 20‑day ($22.79), 50‑day ($19.38) and 200‑day ($20.43) simple moving averages, indicating a short‑term bullish bias. However, the 14‑day RSI of 82 places the stock in overbought territory and the price is hugging the near‑term resistance level of $25.85, suggesting limited upside in the immediate horizon. The MACD remains bullish with a modest histogram (+0.20), and volume is on an upward trend, supporting the recent price strength. On the valuation side, the trailing P/E of 88.8 dwarfs the industry average of 25.5, while the DCF‑derived fair value of $16.87 implies the market is pricing the stock at a roughly 53% premium, flagging a clear overvaluation signal. Forward earnings estimates paint a different picture: a projected EPS of $2.91 translates to a forward P/E of 8.8, hinting at significant earnings growth potential if the company can execute its roadmap.
Fundamentally, TruBridge delivers modest profitability (operating margin 1.97%, net margin 1.26%) and solid cash generation (operating cash flow $36.9M, free cash flow $29.6M), but carries a high debt load (Debt/Equity 93.7) and faces multiple securities‑fraud investigations reported in recent news, adding regulatory and legal headwinds. The stock shows high 30‑day volatility (≈67%) and a beta near market neutrality (0.95), reinforcing a risk‑aware stance. Given the overvalued price, overbought technicals, and pending legal concerns, a cautious short‑term hold is prudent, while the strong forward earnings outlook and cash flow support a more optimistic medium‑ to long‑term view if price corrections bring valuation back in line with fundamentals.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI in overbought territory (82)
  • Price near resistance at $25.85
  • Ongoing securities‑fraud investigations

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Forward EPS growth to $2.91 (forward P/E 8.8)
  • Strong operating and free cash flow generation
  • Resolution of legal/regulatory issues could unlock value

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Healthcare information services sector tailwinds
  • Potential price correction toward DCF fair value (~$16.9)
  • Robust cash generation and low dividend reliance

Key Metrics & Analysis

Financial Health

Profit Margin1.26%
P/E Ratio88.8
ROE2.52%
ROA3.94%
Debt/Equity93.70
P/B Ratio2.1
Op. Cash Flow$37.0M
Free Cash Flow$29.6M
Industry P/E25.5

Technical Analysis

TrendNeutral
RSI82.4
Support$16.99
Resistance$25.85
MA 20$22.79
MA 50$19.38
MA 200$20.43
MACDBullish
VolumeIncreasing
Fear & Greed Index88.54

Valuation

Fair Value$16.87
Target Price$25.67
Upside/Downside-0.28%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.95
Volatility67.40%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.